CARGO Therapeutics stock hits 52-week low at $12.17

Published 13/01/2025, 15:40
CARGO Therapeutics stock hits 52-week low at $12.17

CARGO Therapeutics, a biotechnology firm focused on innovative cancer treatments with a market capitalization of $621 million, has seen its stock price touch a 52-week low, dipping to $12.17. According to InvestingPro analysis, the company maintains a strong liquidity position with a current ratio of 18.95 and holds more cash than debt on its balance sheet. This latest price point reflects a significant downturn from the previous year, with the company's stock experiencing a 1-year change of -33.86%. Investors are closely monitoring CARGO Therapeutics as it navigates through a challenging phase, balancing its research advancements with market expectations. The 52-week low serves as a critical juncture for the company, with analysts setting price targets between $28 and $34. InvestingPro analysis suggests the stock may be undervalued at current levels, with 8 additional exclusive insights available to subscribers.

In other recent news, Cargo Therapeutics has been the subject of significant analyst attention. Clear Street initiated coverage, assigning a Buy rating with a $28 price target, aligning with broader analyst consensus. The firm expressed optimism about Cargo Therapeutics' leading drug candidate, Firi-cel, due to its superior efficacy compared to existing treatments for B-cell malignancies. Clear Street also underscored the blockbuster potential of Firi-cel, estimating peak sales to reach approximately $2.1 billion.

Cargo Therapeutics is eagerly anticipated to release interim results from its pivotal trial. The company's FIRCE-1 trial for Firi-cel reported a substantial increase in patient enrollment and a manufacturing success rate over 95%. Other recent developments include progress with its CRG-023 therapy, securing approximately $110 million from a private investment, and entering a sublease agreement with Vaxcyte, Inc.

Analyst firms TD Cowen and Piper Sandler have maintained their positive ratings, with Piper Sandler reaffirming its Overweight rating based on research supporting the safety profile of CAR-T therapies. Lastly, Cargo Therapeutics announced the appointment of Dr. Kapil Dhingra to its Board of Directors. These are recent developments in the company's operations.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.